Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Since 2018, three medications have been approved by the FDA for use in heavily treatment-experienced or treatment-resistant HIV: ibalizumab, fostemsavir and lenacapavir.

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Lenacapavir for HIV prevention remains investigational and is not approved anywhere globally. Phase 1 studies indicate promising results for once-yearly use. However, further research, including ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...